Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-30

Study Completion Date

2023-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nearly 10,000 people die each year in the United Kingdom from cancer of the lower gullet and stomach, known as known as oesophago- gastric adenocarcinoma (OGC). OGC is detected late as symptoms are non- specific and often mistaken for common problems such as heartburn. This translates to fewer than 2 in every 10 patients diagnosed with OGC living longer than 5 years.

The breath of people with OGC is enriched with volatile chemicals (VOCs) that indicate cancer. When measured in a breath test, it detects OAC 80 out of 100 times. Whilst encouraging, there is scope to improve the detection rate by giving patients a stimulant drink that amplifies the production of tumour specific VOCs only, to increase their detection in the breath test.

The goal of this observational study is to produce an enhanced second-generation breath test with superior ability to detect OGC through augmentation of breath. This will improve long term survival from cancer using an entirely non- invasive test.

All participants (cancer and control participants) will consume an oral stimulant drink (OSD) and provide breath samples pre and post consumption of the drink at set time points (maximum 2 hours after consumption of the drink).

The investigators will compare the breath VOCs from both groups, before and after consumption of the OSD to see if the OSD has a desired augmentation effect and can improve the accuracy of the OGC breath test.

With this second-generation breath test, participants with vague symptoms can undergo a quick, non- invasive test, have samples analysed in a safe and accurate manner and be subsequently stratified based on their risk of having OGC, leading to earlier disease detection and improved clinical outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)

NCT05412758

Volatile Organic Compounds Microbiome Microbioata +7 more

RECRUITING NA

Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma

NCT06669663

OESOPHAGO-GASTRIC CARCINOMA

RECRUITING

AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

NCT07260734

OESOPHAGO-GASTRIC CARCINOMA Oesophageal Adenocarcinoma Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma +5 more

NOT_YET_RECRUITING

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

NCT00526110

Gastrointestinal Diseases

COMPLETED PHASE1/PHASE2

The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma

NCT00674167

Gastric Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction: Early detection of oesophago- gastric adenocarcinoma (OGC) with improved diagnostics is essential to reduce the burden of this aggressive cancer. The breath of people with OAC is enriched with volatile organic compounds (VOC). A breath test based on these VOCs has an 80% sensitivity and 81% specificity of detecting OAC. The diagnostic accuracy may be further improved by using an exogenous stimulant that amplifies the production of OGC specific VOCs. This strategy is known as 'augmentation'. It is possible to compare intra- subject breath (pre and post stimulant) and use the fold increase in VOCs to detect cancer. This is the investigator's novel approach to improving breath test sensitivity and early OGC detection. The biology of the OGC VOCs must be first understood to selectively augment their production.

Background: The OGC lipidome is enriched with phospholipids that are vulnerable to degradation via lipid peroxidation, which is a principal mechanism for endogenous VOC production. Prokaryotic lipids in the OGC microbiome are also vulnerable to peroxidation. Putative drivers of lipid peroxidation are higher in tumour environment. This suggests OGC lipids and/ or prokaryotic lipids may be source compounds for diagnostic VOCs and this mechanism may be augmented.

Aim: to augment the production of OGC VOCs to improve the diagnostic performance of the breath test.

Proposal: 1) A lipidomics study of the onco- microbial lipidome using bespoke mass spectrometry with phenotyping of the corresponding VOCs will identify source lipids that generate diagnostic VOCs, 2) data driven stable isotope experiments to select an augmentation model based on the degradation kinetics of the source lipid in vivo and 3) translating the science to clinic with a study of the augmented breath test in participants with OGC.

Translation of the novel scientific data generated to clinic presents a real opportunity to improve clinical outcomes in people with OGC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breath Test Oesophageal Cancer Gastric Cancer Augmentation Diagnoses Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

All study participants will receive the same formulation, dose and amount of the oral stimulant drink. Breath samples will be taken at baseline and then at the same time points following consumption of the drink.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oesophago- gastric adenocarcinoma patients

Oesophagogastric adenocarcinoma (OG) cancer patients (who are neoadjuvant chemotherapy treatment naïve) will receive 120mls of a sterile oral stimulant drink (OSD) (manufactured by Ingenza ltd), which is an ISO accredited laboratory. The active component of the drink is iron sulphate (5g/l), pH 5-6.

Breath will be taken following an optimised methodology designed by the VOC laboratory at Imperial college London at baseline and then at 30, 60 and 90 minutes following consumption of the drink.

Participants will be nil by mouth for 6 hours prior to the breath test, they can have water up to 2 hours before the breath test.

Group Type EXPERIMENTAL

Oral Stimulant Drink

Intervention Type DIETARY_SUPPLEMENT

please see description of the drink in the arm/ group section

Benign healthy control patients

Age, gender and demographic matched patients who have had a negative oesophagogastroscopy within 1 year which is negative for adenocarcinoma will be recuited into the comparison arm. Patients will be given the same OSD and breath will be sampled at the same time points as the experimental arm.

Group Type ACTIVE_COMPARATOR

Oral Stimulant Drink

Intervention Type DIETARY_SUPPLEMENT

please see description of the drink in the arm/ group section

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Stimulant Drink

please see description of the drink in the arm/ group section

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants should be over 18 years old and up to the maximal age of 90 years , AND:
* Have a confirmed histological diagnosis of oesophageal OR gastric adenocarcinoma at Imperial NHS Healthcare Trust, AND
* Will undergo am oesophagogastroscopy (OGD) as part of their routine clinical care, OR:
* Will undergo surgical resection of their oesophageal or gastric cancer as part of their routine clinical care OR
* Any patient with non- cancerous upper gastrointestinal (benign) problem who will have an OGD OR surgery as part of their routine clinical care at Imperial NHS Trust

Exclusion Criteria

* Participant that lacks capacity or is unable to provide informed consent
* Any participant below 18 years of age or over 90 years of age
* Participants with allergies to any aspect of the metabolic drink
* Participants who have had previous OG surgical resection

Minimum Eligible Age

19 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes